Mapp Biopharmaceutical

Executive Summary

Mapp Biopharmaceutical, founded in 2003 and headquartered in San Diego, is a private biotech company focused on developing novel monoclonal antibody therapeutics for high-consequence viral pathogens. The company addresses critical unmet needs in global health and biodefense, with a pipeline targeting diseases such as Lassa fever, Ebola, and Marburg. Supported by significant partnerships with US government agencies, Mapp leverages its expertise in antibody discovery and engineering to advance candidates from preclinical through clinical development. Its lead program, a Lassa virus monoclonal antibody, has shown promise in non-human primate studies and is progressing toward clinical trials. Mapp's platform is designed to rapidly respond to emerging infectious threats, positioning it as a key player in pandemic preparedness. Despite being privately held with limited public financial disclosures, the company's government collaborations and focus on high-priority pathogens underscore its strategic importance and potential for near-term value inflection. In the near term, Mapp is expected to deliver clinical data from its Lassa fever antibody program, which could de-risk the candidate and attract licensing or partnership interest. Additionally, the company may secure new government contracts under the BARDA or NIH umbrella, providing non-dilutive funding and validation. A potential FDA designation, such as Breakthrough Therapy or Orphan Drug, would further accelerate development. These catalysts, combined with ongoing global health surveillance for outbreak preparedness, position Mapp for significant milestones within the next 12-18 months. However, as a private entity with limited transparency, binary event risk remains moderate.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Trial Results for Lassa Fever Monoclonal Antibody55% success
• Q2 2026New Government Contract for Outbreak Preparedness70% success
• Q3 2026FDA Breakthrough Therapy Designation for Lassa Antibody40% success